Brian Wesley Simons

Brian Wesley Simons

Auto-generated profile, based on publicly available information

Brian Wesley Simons

Department of Urology, James Buchanan Urological Institute, Johns Hopkins University, School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2017 in Science Advances
Verified
Journal Article
Open access
PDF file
CSCraig S. Schneider
Craig S. Schneider
Qingguo XuQingguo Xu
Qingguo Xu
NBNicholas J. Boylan
Nicholas J. Boylan
JCJane Chisholm
Jane Chisholm
BTBenjamin C. Tang
Benjamin C. Tang
JHJustin Hanes
Justin Hanes
Debunking the mucoadhesion myth: Nonsticky particles for enhanced pulmonary drug delivery.

1 December 2012 in Cancer Letters
Verified
Journal Article
Closed access
Ulf Dietrich KahlertUlf Dietrich Kahlert
Ulf Dietrich Kahlert
DMDonata Maciaczyk
Donata Maciaczyk
SDSoroush Doostkam
Soroush Doostkam
BOBrent A. Orr
Brent A. Orr
BSBrian Simons
Brian Simons
JMJaroslaw Maciaczyk
Jaroslaw Maciaczyk

30 April 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MIMichael Ittmann
Michael Ittmann
JHJiaoti Huang
Jiaoti Huang
EREnrico Radaelli
Enrico Radaelli
PMPhilip Martin
Philip Martin
SSSabina Signoretti
Sabina Signoretti
RCRobert D. Cardiff
Robert D. Cardiff
Animal models, particularly mouse models, play a central role in the study of the etiology, prevention, and treatment of human prostate cancer. While tissue culture models are extremely useful in understanding the biology of prostate cancer, they cannot recapitulate the complex cellular interactions within the tumor microenvironment that play a key role in cancer initiation and progression. The National Cancer Institute (NCI) Mouse Models of Human Cancers Consortium convened a group of human and veterinary pathologists to review the current animal models of prostate cancer and make recommendations about the pathologic analysis of these models. More than 40 different models with 439 samples were reviewed, including genetically engineered mouse models, xenograft, rat, and canine models. Numerous relevant models have been developed over the past 15 years, and each approach has strengths and weaknesses. Analysis of multiple genetically engineered models has shown that reactive stroma formation is present in all the models developing invasive carcinomas. In addition, numerous models with multiple genetic alterations display aggressive phenotypes characterized by sarcomatoid carcinomas and metastases, which is presumably a histologic manifestation of epithelial–mesenchymal transition. The significant progress in development of improved models of prostate cancer has already accelerated our understanding of the complex biology of prostate cancer and promises to enhance development of new approaches to prevention, detection, and treatment of this common malignancy. Cancer Res; 73(9); 2718–36. ©2013 AACR.

31 August 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
ZYZachary A. Yochum
Zachary A. Yochum
JCJessica Cades
Jessica Cades
HWHailun Wang
Hailun Wang
SCSuman Chatterjee
Suman Chatterjee
BSBrian W. Simons
Brian W. Simons
TBTimothy Burns
Timothy Burns

15 September 2008 in Oncogene
Verified
Journal Article
Closed access
PDF file
ESE M Schaeffer
E M Schaeffer
LMLuigi Marchionni
Luigi Marchionni
ZHZ Huang
Z Huang
BSB Simons
B Simons
ABA Blackman
A Blackman
DBD M Berman
D M Berman

27 March 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
PKPreethi Korangath
Preethi Korangath
JBJames Barnett
James Barnett
ASAnirudh Sharma
Anirudh Sharma
EHElizabeth T. Henderson
Elizabeth T. Henderson
JSJacqueline Stewart
Jacqueline Stewart
Robert IvkovRobert Ivkov
Robert Ivkov
The factors that influence nanoparticle fate in vivo following systemic delivery remain an area of intense interest. Of particular interest is whether labeling with a cancer-specific antibody ligand (“active targeting”) is superior to its unlabeled counterpart (“passive targeting”). Using models of breast cancer in three immune variants of mice, we demonstrate that intratumor retention of antibody-labeled nanoparticles was determined by tumor-associated dendritic cells, neutrophils, monocytes, and macrophages and not by antibody-antigen interactions. Systemic exposure to either nanoparticle type induced an immune response leading to CD8+ T cell infiltration and tumor growth delay that was independent of antibody therapeutic activity. These results suggest that antitumor immune responses can be induced by systemic exposure to nanoparticles without requiring a therapeutic payload. We conclude that immune status of the host and microenvironment of solid tumors are critical variables for studies in cancer nanomedicine and that nanoparticle technology may harbor potential for cancer immunotherapy.